Any current/future new fundraising through debt or equity?

Current debt levels stand at around INR 260-270 crores, with an average interest rate of about 8.25-8.3%. The company is both taking additional debt and repaying existing debt, keeping net debt stable. Peak debt going forward is forecasted not to exceed INR 300 crores due to ongoing repayments. No explicit mention of any new equity fundraising in the recent call. Focus is currently on stabilizing post recent acquisition (Nerbe) and completing large capex projects rather than raising new funds. No indicated plans for major debt or equity fundraising announced during the call.

Any current/future capex/capital investment/strategic investment?

Tarsons is executing a large capex program totaling around INR 550-600 crores. Approximately INR 525 crores have already been spent; remaining capex to be incurred over the next 6 to 12 months. Major focus is on the Panchla facility with capex around INR 300 crores aimed at manufacturing and growth. The Panchla plant expansion is largely centered on new products (>70%), with <30% capacity addition for existing products. Additional capex of around INR 300 crores is directed towards existing plants like Amta, Jangalpur, and Dhulagarh. A sizable logistics and storage facility is planned but the I

Future growth expectations in sales/revenue/volumes?

The plastic labware industry faced a 30-35% revenue decline post-COVID peak (FY '22), but Tarsons limited decline to 6-7% due to strong market share. Signs of industry recovery are visible with increased order inquiries in domestic and international markets. Tarsons is heavily participating in large RFQs and global tenders, aiming to win more international business in H2 FY '25 and beyond. New Panchla facility (INR300 crores capex) expected to start contributing from H2 FY '25, with full machine installation over next 6-10 months. Global market will play a big role for Panchla’s capacity utili

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth driven by new product introductions and international market expansion, particularly leveraging the Nerbe acquisition and the large Panchla facility. Panchla plant's capacity installation is expected over the next 6-10 months, with meaningful top-line contribution beginning thereafter, enhancing operating leverage. Management anticipates stabilization and recovery in domestic diagnostic sector demand post-COVID. While consolidated EBITDA margins were impacted in Q1 FY25 by several factors (insurance claim provision, product mix, employee expenses, and lower-m

Current/ Expected Orderbook/ Pending Orders?

Tarsons Products Limited does not disclose specific order book or pending order details at the company level. Orders are only reflected in sales once executed, hence no guidance or numbers on order book are provided. The company maintains confidentiality on order details like type, value, or customer identity. Santosh Agarwal stated the current debt is around INR 260-270 crores with ongoing repayments, but this does not provide direct insights on order book. Aryan Sehgal emphasized no disclosure of order specifics, even when orders are received. The company focuses on managing orders daily but

IN US

Sale is live|00:00:00left today

Tarsons Products LtdQ2 FY24Healthcare Equipment & Supplies

Tarsons Products Ltd Q2 FY24 Earnings Call Analysis

Q: Future growth expectations in sales/revenue/volumes?

The plastic labware industry faced a 30-35% revenue decline post-COVID peak (FY '22), but Tarsons limited decline to 6-7% due to strong market share. Signs of industry recovery are visible with increased order inquiries in domestic and international markets. Tarsons is heavily participating in large RFQs and global tenders, aiming to win more international business in H2 FY '25 and beyond. New Panchla facility (INR300 crores capex) expected to start contributing from H2 FY '25, with full machine installation over next 6-10 months. Global market will play a big role for Panchla’s capacity utili

Q: Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth driven by new product introductions and international market expansion, particularly leveraging the Nerbe acquisition and the large Panchla facility. Panchla plant's capacity installation is expected over the next 6-10 months, with meaningful top-line contribution beginning thereafter, enhancing operating leverage. Management anticipates stabilization and recovery in domestic diagnostic sector demand post-COVID. While consolidated EBITDA margins were impacted in Q1 FY25 by several factors (insurance claim provision, product mix, employee expenses, and lower-m

Q: Current/ Expected Orderbook/ Pending Orders?

Tarsons Products Limited does not disclose specific order book or pending order details at the company level. Orders are only reflected in sales once executed, hence no guidance or numbers on order book are provided. The company maintains confidentiality on order details like type, value, or customer identity. Santosh Agarwal stated the current debt is around INR 260-270 crores with ongoing repayments, but this does not provide direct insights on order book. Aryan Sehgal emphasized no disclosure of order specifics, even when orders are received. The company focuses on managing orders daily but

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹270P/E: 51.8Market Cap: ₹1.1K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The plastic labware industry faced a 30-35% revenue decline post-COVID peak (FY '22), but Tarsons limited decline to 6-7% due to strong market share.
→Signs of industry recovery are visible with increased order inquiries in domestic and international markets.
→Tarsons is heavily participating in large RFQs and global tenders, aiming to win more international business in H2 FY '25 and beyond.
→New Panchla facility (INR300 crores capex) expected to start contributing from H2 FY '25, with full machine installation over next 6-10 months.
→Global market will play a big role for Panchla’s capacity utilization; revenues expected to grow as new capacities come online.
→Nerbe acquisition (EUR 10 million company) offers significant synergy potential; management aims for multi-fold growth but exact figures and timelines remain uncertain.
→Domestic diagnostic segment has stabilized after COVID-related demand spike normalization.
→Overall, long-term sector growth expected, with investment focused on expanding manufacturing and international presence.

Margin guidance

Category 3

→The company expects revenue growth driven by new product introductions and international market expansion, particularly leveraging the Nerbe acquisition and the large Panchla facility.
→Panchla plant's capacity installation is expected over the next 6-10 months, with meaningful top-line contribution beginning thereafter, enhancing operating leverage.
→Management anticipates stabilization and recovery in domestic diagnostic sector demand post-COVID.
→While consolidated EBITDA margins were impacted in Q1 FY25 by several factors (insurance claim provision, product mix, employee expenses, and lower-margin trading entity Nerbe Plus), the stand-alone business aims to maintain mid-40% EBITDA margins as scale increases.
→Nerbe margins (~10%-12% EBITDA) are expected to remain steady, with incremental value-addition potentially improving profitability.
→Peak debt is forecasted to stay below INR 300 crores, supporting financial stability.
→Overall, management is cautiously optimistic but notes macro uncertainties and competition as variables impacting future profit growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→Current debt levels stand at around INR 260-270 crores, with an average interest rate of about 8.25-8.3%.
→The company is both taking additional debt and repaying existing debt, keeping net debt stable.
→Peak debt going forward is forecasted not to exceed INR 300 crores due to ongoing repayments.
→No explicit mention of any new equity fundraising in the recent call.
→Focus is currently on stabilizing post recent acquisition (Nerbe) and completing large capex projects rather than raising new funds.
→No indicated plans for major debt or equity fundraising announced during the call.

Order book

Yes

→Tarsons Products Limited does not disclose specific order book or pending order details at the company level.
→Orders are only reflected in sales once executed, hence no guidance or numbers on order book are provided.
→The company maintains confidentiality on order details like type, value, or customer identity.
→Santosh Agarwal stated the current debt is around INR 260-270 crores with ongoing repayments, but this does not provide direct insights on order book.
→Aryan Sehgal emphasized no disclosure of order specifics, even when orders are received.
→The company focuses on managing orders daily but only reports revenues post order fulfillment.
→Overall, no broad or ballpark figures on current or expected order books were shared publicly.

Capex plans

Yes

→Tarsons is executing a large capex program totaling around INR 550-600 crores.
→Approximately INR 525 crores have already been spent; remaining capex to be incurred over the next 6 to 12 months.
→Major focus is on the Panchla facility with capex around INR 300 crores aimed at manufacturing and growth.
→The Panchla plant expansion is largely centered on new products (>70%), with <30% capacity addition for existing products.
→Additional capex of around INR 300 crores is directed towards existing plants like Amta, Jangalpur, and Dhulagarh.
→A sizable logistics and storage facility is planned but the INR 300 crores cited largely pertains to manufacturing, not logistics.
→Machinery installation at Panchla is progressing but delayed due to transit damage; commissioning expected in second half of FY25.
→The new capacities are targeted to start contributing to revenue post-installation, with 6-8 months anticipated for full machine installations.

How does Tarsons Products Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

1Tarsons Products Ltd

Rev 3Mar 3

See full Healthcare Equipment & Supplies sector rankings

Want more stocks like Tarsons Products Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio